Robert Daly, MD
Pulmonary Disease · Greenwood, INNPI 1255311981
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,700 of the $54,341 with a category attached, or 71.2%. GSK accounts for 78.5% of it on its own, with 48 other manufacturers making up the rest. Reporting peaked in 2023 at $15,789 and has fallen 85.3% since, to $2,322 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 972 payments — averaging $55.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$43K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$770
- Grifols USA, LLC$740
- Sanofi$671
- plus $6K from 43 others
What the payments were for
- Speaking & faculty fees$38,70071%
- Food & beverage$15,09428%
- Education$5471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$18,328
- ANORO ELLIPTA$3,600
- BREZTRI$427
- FARXIGA$313
- AIRSUPRA$313
- TEZSPIRE$313
- FASENRA$313
- NUCALA$125
How this compares
$54,341 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 130 | $1,093,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 692 | $614,886 |
| Breo ElliptaFluticasone/Vilanterol | 234 | $138,543 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $110,135 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 133 | $91,034 |
| Spiriva RespimatTiotropium Bromide | 113 | $83,525 |
| Dupixent PenDupilumab | 19 | $77,357 |
| Spiriva HandihalerTiotropium Bromide | 83 | $63,514 |
| EliquisApixaban | 64 | $58,816 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 68 | $56,151 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 80 | $54,785 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $45,830 |
| SymbicortBudesonide/Formoterol Fumarate | 94 | $37,958 |
| OzempicSemaglutide | 26 | $36,940 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 154 | $22,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,185 | $1,287,552391 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $42,659 | $849,2971,079 claims |
| CSL BehringHizentra | $189 | $110,13513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,111 | $83,788141 claims |
| PfizerEliquis | $631 | $58,81664 claims |
| Novo NordiskOzempic | $65 | $36,94026 claims |
| Johnson & JohnsonXarelto | $121 | $20,66220 claims |
| MerckDulera | $142 | $14,75628 claims |
| NovartisEntresto | $273 | $13,91113 claims |
| AbbVieLinzess | $20 | $7,47614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Greenwood
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Umar OsmanGreenwood$19K
- Imad ShawaGreenwood$11K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.